State of Alaska Department of Revenue Acquires 14,065 Shares of Harrow, Inc. $HROW

State of Alaska Department of Revenue lifted its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 807.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,807 shares of the company’s stock after acquiring an additional 14,065 shares during the quarter. State of Alaska Department of Revenue’s holdings in Harrow were worth $774,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of HROW. Penn Capital Management Company LLC bought a new stake in shares of Harrow during the 3rd quarter valued at about $15,717,000. Luxor Capital Group LP bought a new stake in shares of Harrow during the 3rd quarter valued at about $14,807,000. New York State Common Retirement Fund boosted its stake in shares of Harrow by 1,944.7% during the 3rd quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock valued at $10,300,000 after purchasing an additional 203,333 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Harrow by 266.8% during the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock valued at $6,519,000 after purchasing an additional 155,258 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Harrow by 967.6% in the 2nd quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock worth $4,610,000 after acquiring an additional 136,809 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Price Performance

Shares of NASDAQ HROW opened at $39.14 on Thursday. Harrow, Inc. has a fifty-two week low of $21.12 and a fifty-two week high of $54.85. The company has a 50 day simple moving average of $40.21 and a two-hundred day simple moving average of $42.40. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -230.22 and a beta of 0.31. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20.

Analyst Ratings Changes

Several brokerages have recently issued reports on HROW. Cantor Fitzgerald decreased their target price on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Harrow in a research report on Thursday, March 19th. B. Riley Financial reissued a “buy” rating and issued a $65.00 target price (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.86.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.